What is the Market's View on Axim Biotechnologies Inc (AXIM) Stock's Price and Volume Trends Friday?

Axim Biotechnologies Inc (AXIM) stock has fallen 33.33% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Axim Biotechnologies Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AXIM!

See Full AXIM Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AXIM Stock Today?

Axim Biotechnologies Inc (AXIM) stock is unmoved -4.19% while the S&P 500 is lower by -0.24% as of 1:11 PM on Friday, Sep 29. AXIM is flat $0.00 from the previous closing price of $0.02 on volume of 747,747 shares. Over the past year the S&P 500 is up 15.33% while AXIM is lower by -80.00%. AXIM lost -$0.05 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Axim Biotechnologies Inc click here.

More About Axim Biotechnologies Inc

Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications. Click Here to get the full Stock Report for Axim Biotechnologies Inc stock.